Search This Blog

Monday, September 11, 2023

Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate

 

  • Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America
  • Partnership to support Samsung Bioepis pipeline expansion and provide increased access to biosimilars
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)